154. 睡眠時棘徐波活性化を示す発達性てんかん性脳症およびてんかん性脳症 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 8 / 薬物数 : 2 - (DrugBank : 0) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
N-[1-((5-cyanopyridin-2-YL)methyl)-1H-pyrazol-3-YL]-2-[4-(1-(trifluoromethyl)cyclopropyl)phenyl]acetamide
   Neurocrine Biosciences, Inc.
      2022   Phase 2   EUCTR2021-006788-11-DK   Denmark;Germany;Spain;Switzerland;United Kingdom;United States
      -   Phase 2   EUCTR2021-006788-11-DE   Canada;Denmark;France;Germany;Spain;Switzerland;United Kingdom;United States
NBI-827104
   Neurocrine Biosciences
      2022   Phase 2   NCT05301894   Denmark;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   NCT04625101   Canada;Denmark;Spain;Switzerland;United Kingdom;United States
   Neurocrine Biosciences, Inc.
      2022   Phase 2   EUCTR2021-006788-11-DK   Denmark;Germany;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003141-11-ES   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      2021   Phase 2   EUCTR2020-003141-11-DK   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      -   Phase 2   EUCTR2021-006788-11-DE   Canada;Denmark;France;Germany;Spain;Switzerland;United Kingdom;United States
      -   Phase 2   EUCTR2020-003141-11-FR   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States
      -   Phase 2   EUCTR2020-003141-11-DE   Canada;Denmark;France;Germany;Italy;Spain;Switzerland;United Kingdom;United States